Table 2 of
Gnanasekaran, Mol Vis 2020; 26:246-256. Table 2 of
Gnanasekaran, Mol Vis 2020; 26:246-256.
Table 2. Changes in serum concentrations (pg/ml) of inflammatory and angiogenic cytokines after intravitreal ranibizumab in diabetic macular edema.
| Biomarkers | Pre-injection, median (IQR) | Post-injection, median (IQR) | Change, median (IQR) | Match-pairs signed rank test, p value |
|---|---|---|---|---|
| IL-1β | 5.56 (3.6, 8.75) | 2.33 (1.51, 2.89) | −3.6 (−6.67, −1.05) | <0.0001* |
| IL-1ra | 42.49 (5.44, 154.44) | 66.9 (29.42, 81.42) | 0 (−134.33, 46.4) | 0.451 |
| IL-2 | 0.91 (0.91, 0.91) | 0.91 (0.91, 0.91) | 0 (0, 0) | undefined |
| IL-4 | 4.09 (3.29, 5.42) | 4.29 (1.83, 4.98) | −0.68 (−3.46, 1.41) | 0.093 |
| IL-5 | 2.81 (0.82, 24.43) | 2.87 (0.82, 5.91) | 0 (−21.56, 0.52) | 0.278 |
| IL-6 | 1.58 (0.88, 5.36) | 2.61 (1.75, 3.94) | 0.76 (−0.78, 2.36) | 0.389 |
| IL-7 | 4.12 (0.64, 12.34) | 1.65 (0.64, 6.6) | 0 (−7.38, 1.21) | 0.202 |
| IL-8 | 13.91 (7.27, 32.45) | 15.39 (10.43, 17.93) | 2.54 (−16.54, 5.04) | 0.696 |
| IL-9 | 0.76 (0.76, 7.03) | 19.67 (5.36, 27.76) | 18.76 (2.33, 24.33) | 0.0003* |
| IL-10 | 2.62 (2.62, 10.21) | 6.9 (4.06, 8.17) | 3.04 (−0.1, 4.57) | 0.242 |
| IL-12 | 2.22 (2.22, 2.22) | 2.33 (2.1, 3.34) | 0 (−0.49, 1.02) | 0.58 |
| IL-13 | 4.30(1.84, 18.55) | 0.38 (0.38, 0.78) | −2.16 (−18.17, −1.32) | <0.0001* |
| IL-15 | 1.91 (1.91, 1.91) | 1.91 (1.91, 1.91) | 0 (0, 0) | undefined |
| IL-17 | 2.27 (2.27, 2.27) | 2.27 (2.27, 2.27) | 0 (0, 0) | undefined |
| Eotaxin | 187.06 (114.66, 342. 6) | 119.68 (70.47, 207.41) | −19.24 (−96.47, 4.2) | 0.0058 |
| FGFb | 0.6 (0.6, 0.6) | 0.6 (0.6, 0.6) | 0 (0, 0) | 0.157 |
| G-CSF | 64.65 (42.9, 108) | 37.8 (27.3, 46.37) | −41.17 (−72.56, −10.54) | 0.0001* |
| GM-CSF | 0.67 (0.67, 0.67) | 0.67 (0.67, 0.67) | 0 (0, 0) | undefined |
| IFNγ | 241 (103.33, 753.4) | 94.46 (42.04, 118.58) | −192.06 (−668.51, −29.83) | 0.0001* |
| IP-10 | 234.68 (144.16, 285.98) | 158.73 (94.71, 198.64) | −39.68 (−138.39, −16.81) | 0.0003* |
| MCP-1 | 1.62 (1.62, 1.62) | 15.23 (4.55, 23.84) | 12.54 (−1.62, 22.22) | 0.563 |
| MIP-1α | 3.65 (2.62, 11.02) | 1.41 (0.94, 1.88) | −2.54 (−10.55, −1.09) | <0.0001* |
| MIP-1β | 0.28 (0.28, 0.28) | 6.79 (3.74, 14.16) | 6.08 (2.51, 13.1) | 0.0003* |
| PDGFB | 276.25 (161.28, 375.51) | 296.35 (105.09, 465.09) | 29.07 (−76.18, 148.58) | 0.242 |
| RANTES | 303.62 (228.61, 355.61) | 352 (148.03, 512.27) | 99.73 (−140.96, 181.95) | 0.276 |
| TNF-α | 131.09 (100.68, 240.27) | 45.19 (24.04, 68.55) | −73.44 (−175.77, −49.17) | <0.0001* |
| VEGF | 2.55 (2.55, 2.55) | 25.24 (14.51, 41.73) | 22.56 (10.93, 38.66) | 0.0001* |
| EPO | 0 (0, 0) | 0 (0, 2687.73) | 0 (0, 0) | 0.699 |
| SVEGFR-1 | 333.92 (204.99, 440.43) | 500.12 (338.7, 786.91) | 214.76 (53.59, 371.86) | 0.0016* |
| SVEGFR-2 | 6695 (6060.22, 8495.57) | 8674.84 (7364.98, 10,228.7) | 1690.28 (−129.55, 2437.81) | 0.156 |
| EGF | 79.59 (47.38, 125.12) | 64.57 (36.78, 132.55) | 12.04 (−52.42, 43.06) | 0.599 |
| ANG-2 | 0 (0, 0) | 0 (0, 0) | 0 (0,0) | 0.597 |